Cambridge, United States
NED Biosystems, Inc., founded in 2008, is a pioneering company in the Biotechnology, Health Care, and Life Sciences industries, headquartered in the United States. The company's slogan, "Founded to allow patients to achieve and sustain No Evidence of Disease," encapsulates its mission to develop treatments that have minimal toxicity, enhancing patient quality of life.
The company's flagship product, NED-170, addresses the critical gap for cancer patients lacking genetically matched therapy options. This product leverages a comprehensive systems-based approach using repurposed oral agents to target cancer without the typical side effects.
Adaptable to crises, NED Biosystems applied its methodology during the pandemic to create NED-260, a universal antiviral treatment aiming to block broad viral pathways, offering early intervention against severe disease.
The company's recent financial momentum includes a $2.00M Series B investment in August 2018, led by investor Benjamin Griswold.
